(Q53488049)

14 May 2018

title

Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. (English)

1 reference

14 May 2018

author name string

Kenji Nishimura

1

1 reference

14 May 2018

Naoko Arichi

2

1 reference

14 May 2018

Shigeki Tokugawa

3

1 reference

14 May 2018

Iwao Yoshioka

4

1 reference

14 May 2018

Hidefumi Kishikawa

5

1 reference

14 May 2018

Yasuji Ichikawa

6

1 reference

14 May 2018

publication date

1 March 2007

1 reference

14 May 2018

International Journal of Urology

published in

1 reference

14 May 2018

volume

14

1 reference

14 May 2018

issue

3

1 reference

14 May 2018

page(s)

264-267

1 reference

14 May 2018

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

Hormone-refractory (D3) prostate cancer: refining the concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

A re-assessment of the role of combined androgen blockade for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01681.X

10.1111/J.1442-2042.2007.01681.X

21 January 2018

Identifiers

DOI

1 reference

14 May 2018

1 reference

14 May 2018